Are all ALK variants created equal? Clinicopathologic features and outcomes: a propensity-matched study

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Anaplastic lymphoma kinase (ALK) rearrangements define a distinct subgroup of non-small cell lung cancer (NSCLC), accounting for approximately 10% of cases.
• Various EML4-ALK and non-EML4 variants exist, detectable via next-generation sequencing (NGS), and exhibit differential responses to tyrosine kinase inhibitors (TKIs).

Purpose of the Study:

• To investigate the clinicopathologic features and outcomes associated with different Anaplastic Lymphoma Kinase (ALK) variants in non-small cell lung cancer (NSCLC).
• To evaluate treatment responses and survival differences among EML4-ALK variants using a propensity-matched analysis.

Main Methods:

• 113 ALK immunohistochemistry (IHC)-positive non-small cell lung cancer (NSCLC) cases underwent custom panel-based next-generation sequencing (NGS) for Anaplastic Lymphoma Kinase (ALK) variant detection.
• Clinicopathologic features, outcomes, and treatment responses (specifically to crizotinib) were analyzed, employing propensity-matched analyses to control for confounding factors.

Main Results:

• Next-generation sequencing (NGS) identified Anaplastic Lymphoma Kinase (ALK) rearrangements in 80.5% of cases, with EML4-ALK being the most common (98.9%).
• EML4-ALK Variant 1 (35%) and Variant 3 (25%) were the most frequent variants. A novel EML4-ALK variant resistant to crizotinib was identified.
• While Variant 1 showed a higher occurrence of metastases, propensity-matched analyses revealed no significant difference in overall survival (OS) or progression-free survival (PFS) between Variant 1 and Variant 3, contrary to existing literature.

Conclusions:

• This study presents a comprehensive dataset on Anaplastic Lymphoma Kinase (ALK) variants in non-small cell lung cancer (NSCLC), highlighting clinical and outcome disparities.
• The application of a propensity-weighted model is crucial for accurately comparing outcomes between ALK variants, particularly demonstrating no prognostic difference between Variant 1 and Variant 3.
• Findings suggest that current treatment strategies may not differentiate prognostically between EML4-ALK Variant 1 and Variant 3, warranting further investigation into targeted therapies.